Literature DB >> 7993072

Inhibition of human adenoviruses by 1-(2'-hydroxy-5'-methoxybenzylidene)amino-3-hydroxyguanidine tosylate.

M B Hui1, E J Lien, M D Trousdale.   

Abstract

Antiviral activities of four Schiff bases of aminohydroxyguanidine, designated ML1, ML4, ATL14 and LK11, were tested against human adenovirus types 5 and 8 (Ad5 and Ad8) in A549 cells by plaque reduction and virus yield reduction methods. Compound (ML1 1-(2'-hydroxy-5'-methoxybenzylidene)amino-3-hydroxyguanidine tosylate gave the best therapeutic indices (TC50/IC50) of 27.2 and 17.8 for Ad5 and Ad8, respectively. Pretreatment of cells with ML1 did not affect the adsorption nor the penetration of virus. Ultrastructure studies showed that only the drug treated infected cells had unidentified irregular shaped electron dense structures that might be drug altered viral macromolecules that were not assembled into complete infectious virus particles. Since these compounds have metal chelating properties, their antiviral activity may involve the early IA (EIA) gene which encodes a viral protein of 289 amino acid which has a zinc finger moiety that is required for its transactivation activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7993072      PMCID: PMC7134180          DOI: 10.1016/0166-3542(94)90074-4

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  17 in total

1.  Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro.

Authors:  Y J Gordon; E Romanowski; T Araullo-Cruz; L Seaberg; S Erzurum; R Tolman; E De Clercq
Journal:  Antiviral Res       Date:  1991-07       Impact factor: 5.970

Review 2.  Ribonucleotide reductase inhibitors as anticancer and antiviral agents.

Authors:  E J Lien
Journal:  Prog Drug Res       Date:  1987

3.  Adenovirus infections in patients undergoing bone-marrow transplantation.

Authors:  A F Shields; R C Hackman; K H Fife; L Corey; J D Meyers
Journal:  N Engl J Med       Date:  1985-02-28       Impact factor: 91.245

4.  Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.

Authors:  J G Cory; G L Carter; P E Bacon; A T'ang; E J Lien
Journal:  Biochem Pharmacol       Date:  1985-08-01       Impact factor: 5.858

5.  Gastroenteritis associated with enteric type adenovirus in hospitalized infants.

Authors:  R H Yolken; F Lawrence; F Leister; H E Takiff; S E Strauss
Journal:  J Pediatr       Date:  1982-07       Impact factor: 4.406

6.  An experimental animal model of adenovirus-induced ocular disease. The cotton rat.

Authors:  J C Tsai; G Garlinghouse; P J McDonnell; M D Trousdale
Journal:  Arch Ophthalmol       Date:  1992-08

7.  Adenovirus infection in the immunocompromised patient.

Authors:  J M Zahradnik; M J Spencer; D D Porter
Journal:  Am J Med       Date:  1980-05       Impact factor: 4.965

8.  Outbreak of infantile gastroenteritis due to type 40 adenovirus.

Authors:  S Chiba; S Nakata; I Nakamura; K Taniguchi; S Urasawa; K Fujinaga; T Nakao
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

9.  Optimization of the Schiff bases of N-hydroxy-N'-aminoguanidine as anticancer and antiviral agents.

Authors:  A T'ang; E J Lien; M M Lai
Journal:  J Med Chem       Date:  1985-08       Impact factor: 7.446

10.  The 289-amino acid E1A protein of adenovirus binds zinc in a region that is important for trans-activation.

Authors:  J S Culp; L C Webster; D J Friedman; C L Smith; W J Huang; F Y Wu; M Rosenberg; R P Ricciardi
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more
  2 in total

1.  Interaction of the human adenovirus proteinase with its 11-amino acid cofactor pVIc.

Authors:  M L Baniecki; W J McGrath; S M McWhirter; C Li; D L Toledo; P Pellicena; D L Barnard; K S Thorn; W F Mangel
Journal:  Biochemistry       Date:  2001-10-16       Impact factor: 3.162

2.  In vitro and in vivo activities of anti-influenza virus compound T-705.

Authors:  Y Furuta; K Takahashi; Y Fukuda; M Kuno; T Kamiyama; K Kozaki; N Nomura; H Egawa; S Minami; Y Watanabe; H Narita; K Shiraki
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.